1. Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy.
Mattavelli I, Patuzzo R, Torri V, Gallino G, Maurichi A, Lamera M, Valeri B, Bolzonaro E, Barbieri C, Tolomio E, Moglia D, Nespoli AM, Galeone C, Saw R, Santinami M.
Eur J Surg Oncol. 2017 Aug;43(8):1536-1541. doi: 10.1016/j.ejso.2017.05.013. Epub 2017 May 25.
2. Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells.
Tuccitto A, Tazzari M, Beretta V, Rini F, Miranda C, Greco A, Santinami M, Patuzzo R, Vergani B, Villa A, Manenti G, Cleris L, Giardiello D, Alison M, Rivoltini L, Castelli C, Perego M.
Stem Cells. 2016 Oct;34(10):2449-2460. doi: 10.1002/stem.2413. Epub 2016 Jun 28.
3. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.
Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C, Giovannoni L, Elia G, Neri D, Maio M, Santinami M.
Cancer Immunol Immunother. 2015 Aug;64(8):999-1009. doi: 10.1007/s00262-015-1704-6. Epub 2015 May 14.
4. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
Mozzillo N, Pasquali S, Santinami M, Testori A, Di Marzo M, Crispo A, Patuzzo R, Verrecchia F, Botti G, Montella M, Rossi CR, Caracò C.
Eur J Surg Oncol. 2015 Jul;41(7):823-9. doi: 10.1016/j.ejso.2015.02.005. Epub 2015 Mar 11.
5. Armed antibodies for cancer treatment: a promising tool in a changing era.
Danielli R, Patuzzo R, Ruffini PA, Maurichi A, Giovannoni L, Elia G, Neri D, Santinami M.
Cancer Immunol Immunother. 2015 Jan;64(1):113-21. doi: 10.1007/s00262-014-1621-0. Epub 2014 Oct 15. Review.
6. Prediction of survival in patients with thin melanoma: results from a multi-institution study.
Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, Gallino G, Tolomio E, Tragni G, Valeri B, Anichini A, Mortarini R, Moglia D, Pellacani G, Bassoli S, Longo C, Quaglino P, Pimpinelli N, Borgognoni L, Bergamaschi D, Harwood C, Zoras O, Santinami M.
J Clin Oncol. 2014 Aug 10;32(23):2479-85. doi: 10.1200/JCO.2013.54.2340. Epub 2014 Jul 7.
7. Number of excised lymph nodes as a quality assurance measure for lymphadenectomy in melanoma.
Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Macripò G, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M.
JAMA Surg. 2014 Jul;149(7):700-6. doi: 10.1001/jamasurg.2013.5676.
8. Accuracy and prognostic value of sentinel lymph node biopsy in head and neck melanomas.
Patuzzo R, Maurichi A, Camerini T, Gallino G, Ruggeri R, Baffa G, Mattavelli I, Tinti MC, Crippa F, Moglia D, Tolomio E, Maccauro M, Santinami M.
J Surg Res. 2014 Apr;187(2):518-24. doi: 10.1016/j.jss.2013.10.037. Epub 2013 Oct 23.
9. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study.
Pasquali S, Mocellin S, Mozzillo N, Maurichi A, Quaglino P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M, Rossi CR.
J Clin Oncol. 2014 Mar 20;32(9):935-41. doi: 10.1200/JCO.2013.50.7681. Epub 2014 Feb 10.
10. The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis.
Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Quaglino P, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M.
Ann Oncol. 2014 Jan;25(1):240-6. doi: 10.1093/annonc/mdt510.
11. Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.
Vallacchi V, Vergani E, Camisaschi C, Deho P, Cabras AD, Sensi M, De Cecco L, Bassani N, Ambrogi F, Carbone A, Crippa F, Vergani B, Frati P, Arienti F, Patuzzo R, Villa A, Biganzoli E, Canevari S, Santinami M, Castelli C, Rivoltini L, Rodolfo M.
Cancer Res. 2014 Jan 1;74(1):130-40. doi: 10.1158/0008-5472.CAN-13-1672.
12. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes.
Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, Maggioni D, Fontana R, Mukenge S, Rivoltini L, Rigamonti G, Mercuri SR, Nicoletti R, Maschio AD, Gianolli L, Fazio F, Marchianò A, Florio AD, Maio M, Salomoni M, Gallo-Stampino C, Fiacco MD, Lambiase A, Coulie PG, Patuzzo R, Parmiani G, Traversari C, Bordignon C, Santinami M, Bregni M.
Int J Cancer. 2013 Jun 1;132(11):2557-66. doi: 10.1002/ijc.27939. Epub 2012 Dec 13.
13. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response.
Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, Chiarion-Sileni V, Tragni G, Santinami M, Vergani B, Villa A, Berti E, Umansky L, Beckhove P, Umansky V, Parmiani G, Rivoltini L, Castelli C.
Cancer Immunol Immunother. 2013 May;62(5):897-908. doi: 10.1007/s00262-013-1397-7. Epub 2013 Apr 16.
14. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma.
Papadia F, Basso V, Patuzzo R, Maurichi A, Di Florio A, Zardi L, Ventura E, González-Iglesias R, Lovato V, Giovannoni L, Tasciotti A, Neri D, Santinami M, Menssen HD, De Cian F.
J Surg Oncol. 2013 Feb;107(2):173-9. doi: 10.1002/jso.23168. Epub 2012 Jun 4.
15. The use of polytetrafluoroethylene to facilitate the vascular access in recurrent melanoma to limbs.
Ruggeri R, Camerini T, Patuzzo R, Maurichi A, Pirovano R, Mattavelli I, Crippa F, Tolomio E, Moglia D, Di Florio A, Santinami M.
Int J Surg Case Rep. 2013;4(1):40-3. doi: 10.1016/j.ijscr.2012.08.013. Epub 2012 Sep 27.
16. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides.
Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, Lombardo C, Tragni G, Santinami M, Parmiani G, Rivoltini L.
Clin Cancer Res. 2012 Dec 1;18(23):6485-96. doi: 10.1158/1078-0432.CCR-12-1516. Epub 2012 Oct 2.
17. Pure desmoplastic melanoma: a melanoma with distinctive clinical behavior.
Maurichi A, Miceli R, Camerini T, Contiero P, Patuzzo R, Tragni G, Crippa F, Romanidis K, Ruggeri R, Carbone A, Santinami M.
Ann Surg. 2010 Dec;252(6):1052-7. doi: 10.1097/SLA.0b013e3181efc23c.
18. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
Anichini A, Molla A, Vegetti C, Bersani I, Zappasodi R, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Pircher H, Di Nicola M, Mortarini R.
Cancer Res. 2010 Nov 1;70(21):8378-87. doi: 10.1158/0008-5472.CAN-10-2028. Epub 2010 Sep 21.
19. Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells.
Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, Carbone A, Santinami M, Patuzzo R, Mina PD, Villa A, Pratesi G, Cossa G, Perego P, Daidone MG, Alison MR, Parmiani G, Rivoltini L, Castelli C.
J Invest Dermatol. 2010 Jul;130(7):1877-86. doi: 10.1038/jid.2010.69. Epub 2010 Apr 8.
20. Single-institution series of early-stage Merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone.
Bajetta E, Celio L, Platania M, Lo Vullo S, Patuzzo R, Maurichi A, Santinami M.
Ann Surg Oncol. 2009 Nov;16(11):2985-93. doi: 10.1245/s10434-009-0615-1. Epub 2009 Jul 16.
21. Multipeptide vaccination in cancer patients.
Pilla L, Rivoltini L, Patuzzo R, Marrari A, Valdagni R, Parmiani G.
Expert Opin Biol Ther. 2009 Aug;9(8):1043-55. doi: 10.1517/14712590903085109. Review.
22. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?
Iero M, Filipazzi P, Castelli C, Belli F, Valdagni R, Parmiani G, Patuzzo R, Santinami M, Rivoltini L.
Cancer Immunol Immunother. 2009 Jul;58(7):1159-67. doi: 10.1007/s00262-008-0610-6. Epub 2008 Nov 8.
23. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage.
Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Anichini A.
Clin Cancer Res. 2009 Jun 15;15(12):4085-94. doi: 10.1158/1078-0432.CCR-08-3323. Epub 2009 Jun 9.
24. Radical dissection after positive groin sentinel biopsy in melanoma patients: rate of further positive nodes.
Santinami M, Carbone A, Crippa F, Maurichi A, Pellitteri C, Ruggeri R, Zoras O, Patuzzo R.
Melanoma Res. 2009 Apr;19(2):112-8. doi: 10.1097/CMR.0b013e328329fe7d.
25. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.
Daniotti M, Vallacchi V, Rivoltini L, Patuzzo R, Santinami M, Arienti F, Cutolo G, Pierotti MA, Parmiani G, Rodolfo M.
Int J Cancer. 2007 Jun 1;120(11):2439-44.
26. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival.
Cascinelli N, Bombardieri E, Bufalino R, Camerini T, Carbone A, Clemente C, Lenisa L, Mascheroni L, Maurichi A, Pennacchioli E, Patuzzo R, Santinami M, Tragni G.
J Clin Oncol. 2006 Sep 20;24(27):4464-71.
27. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
Pilla L, Patuzzo R, Rivoltini L, Maio M, Pennacchioli E, Lamaj E, Maurichi A, Massarut S, Marchianò A, Santantonio C, Tosi D, Arienti F, Cova A, Sovena G, Piris A, Nonaka D, Bersani I, Di Florio A, Luigi M, Srivastava PK, Hoos A, Santinami M, Parmiani G.
Cancer Immunol Immunother. 2006 Aug;55(8):958-68. Epub 2005 Oct 8.
28. Vaccination: role in metastatic melanoma.
Pilla L, Valenti R, Marrari A, Patuzzo R, Santinami M, Parmiani G, Rivoltini L.
Expert Rev Anticancer Ther. 2006 Aug;6(8):1305-18. Review.
29. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D’Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L.
Cancer Res. 2006 May 1;66(9):4943-51.
30. Lymphoscintigraphy with intraoperative gamma probe sentinel node detection: clinical impact in patients with head and neck melanomas.
Maccauro M, Villano C, Aliberti G, Ferrari L, Castellani MR, Patuzzo R, Tshering D, Santinami M, Bombardieri E.
Q J Nucl Med Mol Imaging. 2005 Sep;49(3):245-51.
31. Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles.
Mortarini R, Scarito A, Nonaka D, Zanon M, Bersani I, Montaldi E, Pennacchioli E, Patuzzo R, Santinami M, Anichini A.
Cancer Res. 2005 Apr 15;65(8):3428-36.
32. Heat shock proteins and their use as anticancer vaccines.
Parmiani G, Testori A, Maio M, Castelli C, Rivoltini L, Pilla L, Belli F, Mazzaferro V, Coppa J, Patuzzo R, Sertoli MR, Hoos A, Srivastava PK, Santinami M.
Clin Cancer Res. 2004 Dec 15;10(24):8142-6. Review. No abstract available.
33. Pigmented spindle-cell nevus: a melanoma simulator.
Maurichi A, Baldi M, Bartoli C, Bono A, Camerini T, Moglia D, Patuzzo R, Pennacchioli E, Tragni G, Santinami M.
Dermatol Online J. 2004 Oct 15;10(2):5. No abstract available.
34. [Impact of sentinel lymph node biopsy on the treatment of melanoma].
Santinami M, Baldi M, Tragni G, Maurichi A, Moglia D, Bono A, Bartoli C, Patuzzo R, Pennacchioli E, Cascinelli N.
Tumori. 2003 Jul-Aug;89(4 Suppl):273-5. Italian.
35. World Health Organization experience in the treatment of melanoma.
Cascinelli N, Santinami M, Maurichi A, Patuzzo R, Pennacchioli E.
Surg Clin North Am. 2003 Apr;83(2):405-16. Review.
36. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study.
Guadagni S, Santinami M, Patuzzo R, Pilati PL, Miotto D, Deraco M, Rossi CR, Fiorentini G, Di Filippo F, Valenti M, Amicucci G.
Melanoma Res. 2003 Feb;13(1):51-8.
37. Impact of clinical trials on the treatment of melanoma.
Santinami M, Maurichi A, Patuzzo R, Pennacchioli E, Cascinelli N.
Surg Oncol Clin N Am. 2001 Oct;10(4):935-47, xi.
38. Sentinel node biopsy and selective lymph node dissection in cutaneous melanoma patients.
Lenisa L, Santinami M, Belli F, Clemente C, Mascheroni L, Patuzzo R, Gallino G, Bergonzi M, Rao S, Polverelli M, Morelli R, Landi G, Cascinelli N.
J Exp Clin Cancer Res. 1999 Mar;18(1):69-74.
39. Total rectal resection, mesorectum excision, and coloendoanal anastomosis: a therapeutic option for the treatment of low rectal cancer.
Leo E, Belli F, Andreola S, Baldini MT, Gallino GF, Giovanazzi R, Mascheroni L, Patuzzo R, Vitellaro M, Lavarino C, Bufalino R.
Ann Surg Oncol. 1996 Jul;3(4):336-43.
40. [Specialization in Europe: a new perspective].
Patuzzo R.
Minerva Chir. 1995 Sep;50(9 Suppl):161-2. Italian. No abstract available.
41. Comparison between pylorus-preserving and Whipple pancreatoduodenectomy.
Zerbi A, Balzano G, Patuzzo R, Calori G, Braga M, Di Carlo V.
Br J Surg. 1995 Jul;82(7):975-9.
42. Total rectal resection and colo-anal anastomosis for low rectal tumours: comparative results in a group of young and old patients.
Leo E, Audisio RA, Belli F, Vitellaro M, Baldini MT, Mascheroni L, Patuzzo R, Rigillo G, Rebuffoni G, Filiberti A, et al.
Eur J Cancer. 1994;30A(8):1092-5.
43. [Maintenance therapy with beta-methyldigoxin in the elderly. A study of 40 patients].
Tellini U, Conati G, Battistoni A, Pedron S, Schinella M, Cacace C, Patuzzo R.
Minerva Cardioangiol. 1991 Mar;39(3):81-5. Italian.